Henry Schein Medical has entered an agreement with Cerebral Assessment Systems (CAS) to distribute Cognivue, the first computerised cognitive assessment screening device that helps practitioners to monitor current brain health and also future reversible dementia.
Cleared by the US Food and Drug Administration (FDA), the device is designed to detect early signs of dementia caused by sleep disorders, infection, systemic illness, and mood disorders.
The fully automated solution, Cognivue, displays controlled visual stimuli on a computer screen, which enables practitioners conducting a quantitative analysis of brain health to derive a composite score of overall brain functional integrity.
The device helps summarise the results on an easily interpreted report that is stored in the cloud, while it also offers a single quantitative score of brain health, allowing physicians to identify potential issues and address them before they get worse.
Global Medical Group president Bridget Ross said: “Our team is committed to not only leveraging our strong distribution network to help healthcare professionals gain greater access to this innovative technology, but also working with forward-thinking leaders such as CAS to help practitioners focus on delivering high-quality patient care for dementia.”
Cognivue monitors and measures how the brain processes information and is customised based on the individual patient, calibrating levels of difficulty based on how well a patient’s brain is performing.
It produces fast and accurate results of the patient’s visual and motor capabilities.
Cognivue creator Dr Charles Duffy said: “Routine measurement of cognitive function should be available to all patients in order to detect discrepancies in brain functionality and then act on them as soon as possible.
“With Henry Schein Medical, our goal is to distribute the device to all the practitioners looking for a solution that makes the assessment of cognitive function as routine as having your blood pressure taken.
“Although an early diagnosis does not solve the cure, minimising the toll dementia takes on patients, by addressing some of the potential causes associated with this condition, is the next best option.”